IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Neurotrope, Inc. and Encourages Investors with Losses to Contact the Firm

IRVINE, Calif., May 30, 2017 /PRNewswire/ -- Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Neurotrope, Inc. ("Neurotrope" or the "Company") (Nasdaq: NTRP). Investors who purchased or otherwise acquired shares between January 7, 2016 and April 28, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm in advance of the July 17, 2017 lead plaintiff motion deadline.

If you purchased Neurotrope shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

According to the Complaint, throughout the Class Period, Neurotrope made false and/or misleading statements and/or failed to disclose material adverse information about the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, the Company announced "positive top-line results" of the focal Phase 2b trials of Bryostatin-1, mentioning "improvement in patients with moderate to severe Alzheimer's disease." The trial data negates these statements, however, as the top-line data relating to the 20-microgram dose of Bryostatin-1 did not produce statistically significant results. Neurotrope also allegedly failed to disclose statements about the efficacy of the 40-microgram dose in connection with its primary and secondary endpoints. Upon release of this news to the public, Neurotrope's stock price dropped materially, which harmed investors according to the Complaint.

If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/important-equity-alert-khang--khang-llp-announces-securities-class-action-lawsuit-against-neurotrope-inc-and-encourages-investors-with-losses-to-contact-the-firm-300465469.html

SOURCE Khang & Khang LLP